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 Curcumin Requires Tumor Necrosis Factor   
Signaling to Alleviate Cognitive Impairment 
Elicited by Lipopolysaccharide 
 E.M. Kawamoto a    C. Scavone b    M.P. Mattson a    S. Camandola a 
 a  Laboratory of Neurosciences, National Institute on Aging, Intramural Research Program,  Baltimore, Md. , USA; 
 b  Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo,  São Paulo , Brazil 
against glutamate-induced excitotoxicity by a mechanism 
requiring TNFR2 activation. Our results suggest the possibil-
ity that therapeutic approaches against cognitive decline 
designed to selectively enhance TNFR2 signaling are likely to 
be more beneficial than the use of anti-inflammatory drugs 
per se.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 The activation of innate immune cells in the central 
nervous system (CNS), principally microglia, and subse-
quently the generation of cytokines [e.g. tumor necrosis 
factor   (TNF-  ), interleukin (IL)-1  , and IL-6] and reac-
tive oxygen species are major components of the neuro-
inflammatory response to injury, infection and neu-
rodegenerative disease  [1] . Increasing evidence suggests 
that local inflammatory processes contribute to neuronal 
dysfunction and associated neurological symptoms in 
neurodegenerative disorders, stroke, traumatic brain in-
jury and HIV dementia  [2–4] . However, the assumption 
that pro-inflammatory molecules exert only detrimental 
effects on CNS function has been challenged by evidence 
that cytokines play roles in cognition and synaptic plastic-
ity  [5] . For example, it was recently reported that IL-1  is 
essential for physiological regulation of memory  [6] . Ge-
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 Abstract 
 A decline in cognitive ability is a typical feature of the normal 
aging process, and of neurodegenerative disorders such
as Alzheimer’s, Parkinson’s and Huntington’s diseases. Al-
though their etiologies differ, all of these disorders involve 
local activation of innate immune pathways and associated 
inflammatory cytokines. However, clinical trials of anti-in-
flammatory agents in neurodegenerative disorders have 
been disappointing, and it is therefore necessary to better 
understand the complex roles of the inflammatory process 
in neurological dysfunction. The dietary phytochemical cur-
cumin can exert anti-inflammatory, antioxidant and neuro-
protective actions. Here we provide evidence that curcumin 
ameliorates cognitive deficits associated with activation of 
the innate immune response by mechanisms requiring func-
tional tumor necrosis factor   receptor 2 (TNFR2) signaling. 
In vivo, the ability of curcumin to counteract hippocampus-
dependent spatial memory deficits, to stimulate neuropro-
tective mechanisms such as upregulation of BDNF, to de-
crease glutaminase levels, and to modulate N-methyl- D -as-
partate receptor levels was absent in mice lacking functional 
TNFRs. Curcumin treatment protected cultured neurons 
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netic ablation or blockage of the IL-1  receptor impairs 
long-term potentiation and hippocampus-dependent 
memory  [7, 8] , while lL-1  administration improves avoid-
ance memory and contextual fear conditioning  [7] . Mice 
deficient in IL-6 display impaired hippocampus-depen-
dent and -independent memory  [9] . TNF-  , tumor necro-
sis factor   receptor 1 (TNFR1) and TNFR2 knockout 
mice all exhibit learning and memory retention impair-
ment, with a more pronounced phenotype in mice devoid 
of TNF-  signaling  [5, 10] . These findings indicate that 
the role played by glia and neuroinflammatory molecules 
is far more complex than was previously appreciated.
 Although neuroinflammation is associated with neu-
ropathologies and cognitive decline, clinical trials using 
anti-inflammatory drugs have not been encouraging. For 
example, although epidemiological data suggested that 
nonsteroidal anti-inflammatory drugs may reduce the 
risk for Alzheimer’s disease (AD)  [11–13] , large random-
ized, placebo-controlled clinical trials using both steroi-
dal and nonsteroidal drugs yielded negative results  [14] 
and in a few cases accelerated progression of the disease 
 [15, 16] .
 The therapeutic use of natural compounds in Western 
medicine has increased as a result of controlled studies 
substantiating beneficial effects of some such natural 
products in experimental disease models  [17, 18] . Cur-
cumin, the principal polyphenol of the spice turmeric 
 (Curcuma longa), exhibits anti-inflammatory, antioxi-
dant, antitumor, metal-chelating, neuroprotective and 
antiamyloidogenic properties  [19] . Because of its pleiotro-
pic actions  [20] and potential ability to preserve cognitive 
performance in the elderly  [21] , we assessed the effect of 
curcumin on cognitive impairment elicited by activation 
of toll-like receptor 4 (TLR4), a prominent component of 
the innate immune system, by bacterial lipopolysaccha-
ride (LPS). TLR4 plays important roles in the response of 
CNS cells to infection and tissue injury  [22] , and is also 
implicated in local inflammatory processes in neurode-
generative diseases  [23] . Here we show that curcumin al-
leviates LPS-induced cognitive impairment by a mecha-
nism requiring TNF-  signaling via TNFR2.
 Animals and Methods 
 Animals and Treatments 
 Adult 12- to 14-week-old male TNFR1 and TNFR2 double 
knockout (DKO) and control background (C57BL/6J) (WT) mice 
were kept under a 12-hour light/12-hour dark cycle and allowed 
free access to food and water. All treatments were administered 
between 8: 00 and 11: 00 AM. Each animal received 50 mg/kg of 
curcumin (Sigma-Aldrich, St. Louis, Mo., USA) intraperitoneally 
for 4 days followed by a single 250   g/kg LPS (O111:B4) (Sigma-
Aldrich) dose 2 h after the last curcumin administration. The LPS 
and curcumin doses used in this study have been reported to in-
duce memory impairment and neuroprotection, respectively, in 
murine experimental models  [24, 25] . Based on the experimental 
end point, mice were euthanized either 4 h or 7 days after LPS ad-
ministration. This research was performed according to guidelines 
in the NIH Guide for the Care and Use of Laboratory Animals.
 Morris Water Maze 
 The test was performed as previously described  [26] . Mice 
were trained in a circular tank containing water (22  8 1  °  C) ren-
dered opaque by the addition of nontoxic paint (Palmer Paints 
Products Inc., Mich., USA). Spatial visual clues were provided in 
the form of differently shaped objects on the walls of each quad-
rant. An escape platform (10  ! 10 cm) was submerged approxi-
mately 1 cm below the surface of the water, 10 cm from the edge 
of the tank at a position designated as quadrant 3 (target quad-
rant). The swimming path length was monitored with a Video-
mex tracking system, and data were collected using Videomex 
Water Maze Software (Columbus Instruments, Ohio, USA). The 
training period consisted of four 60-second trials per day, with 
each mouse released into the water at a different quadrant for each 
trial. Learning retention (spatial memory) was measured in two 
probe trials at 4 and 24 h after the last training session. For both 
probe trials, the platform was removed and mice were allowed to 
swim freely in the tank for 60 s.
 Open Field Test 
 Mice were placed in the center of an open field apparatus (40 
 ! 40 cm), and ambulation scores (the number of squares crossed) 
and the number of rearings and peepings were measured during 
a 15-min period over 3 days after LPS treatment.
 Rotarod 
 Motor skills were tested using the ENV-577M Rotarod system 
(Med Associates, Georgia, Vt., USA). The time spent on the rod 
and the number of falls from the rotating rod was measured for 
each animal during 300-second trials (the speed of rod rotation 
was increased progressively from 3 to 30 rpm during the 300-sec-
ond period).
 Fear Conditioning 
 Mice were habituated to the testing room for 5 consecutive 
days. During the training session, mice were placed in a contex-
tual conditioning chamber (model MED-VFC-NIR-M; Med As-
sociates) and allowed to explore for 2 min. The mice were sub-
jected to 3 sessions of a 30-second neutral discrete stimulus (con-
ditioned stimulus, audio tone 6 kHz, 70 dB), followed by 2 s of
a motivationally significant stimulus (unconditioned stimulus; 
foot shock, 0.5 mA). Each session of conditioned and uncondi-
tioned stimulus pairings was separated by 30 s. On the following 
day during the contextual fear session, mice were returned in the 
same conditioning cage for 5 min without any stimulus. In the 
cued session, mice were placed in the chamber in a different con-
text and allowed to explore for 5 min before being subjected to 5 
audio tones over a 5-min period. The percentage of time freezing 
was recorded in both sessions and used as an index of either con-
textual or cued memory.
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 Primary Cultures and Experimental Treatments 
 Primary hippocampal and cortical neuronal cells were pre-
pared as described  [27] . For all in vitro experiments cells were 
pretreated for 24 h with vehicle dimethyl sulfoxide or 10   M cur-
cumin and then exposed to 200   M glutamate. Recombinant 
TNFR2 (1   g/ml) (A.G. Scientific, San Diego, Calif., USA) and
1   g/ml TNFR2 neutralizing antibody (Santa Cruz Biotechnol-
ogy, Calif., USA) or control IgG were added at 24 h and 30 min 
before glutamate challenge, respectively. Cell survival was as-
sessed 24 h after addition of glutamate using a CellTiter 96 AQue-
ous Assay System (Promega, Madison, Wisc., USA) and lactate 
dehydrogenase activity assay (Roche, Nutley, N.J., USA).
 Protein Extraction and Immunoblot Analysis 
 Tissue, whole-cell extracts and nuclear fractions were
prepared as described  [28] . The primary antibodies used in this 
study were: Actin, NR1 and RelA (Sigma-Aldrich); EAAT2 and
pSer897-NR1 (Cell Signaling, Danvers, Mass., USA); hnRNP
C1/C2, TNFR1 and TNFR2 (Santa Cruz Biotechnology); EAAT3 
(Abbiotec, San Diego, Calif., USA); GFAP (AbCam, Cambridge, 
Mass., USA); GluR1 (Upstate, Lake Placid, N.Y., USA);
pSer845GluR1 (Millipore, Billerica, Mass., USA), and NOS (BD 
Transduction, Franklin Lakes, N.J., USA).
 RNA Extraction and Real-Time PCR 
 RNA was isolated using Trizol (Invitrogen) and purified with 
an RNA Micro Kit (Qiagen, Valencia, Calif., USA). Real-time PCR 
analysis was performed with a PTC 200 Pelthier Thermo Cycler 
and Chromo 4 Fluorescent Detector (BioRad, Hercules, Calif., 
USA), and Sybr  Green PCR Master Mix according to the manu-
facturer’s instructions (Applied Biosystems, Foster City, Calif., 
USA). Each reaction included 3   l of diluted (1: 4) cDNA and was 
performed in duplicate. The comparative Ct method was used to 
determine the normalized changes of the target gene relative to a 
calibrator reference. The genes analyzed in this study were: 
mBDNF (I:NM_007540, II:NM_001048139, III:NM_001048141, 
IV:NM_001048142), mGLS1 (NM_001081081), mHPRT (NM_
013556), and mTrkB (NM_001025074).
 Statistical Analysis 
 Data are expressed as mean and SEM. Statistical comparisons 
were performed by analysis of variance followed by post hoc New-
man-Keuls test, using a Prism software package (Graphpad Soft-
ware, San Diego, Calif., USA).
 Results 
 Curcumin Ameliorates LPS-Induced Memory 
Impairment 
 The experimental design with regard to timing of ad-
ministration of curcumin and LPS is shown in  figure 1 a. 
Mice pretreated with vehicle or curcumin were adminis-
tered one dose of vehicle or LPS to activate immunocom-
petent brain cells  [24] . The effect of curcumin and LPS 
administration on learning and memory was evaluated 
using the water maze test. No differences were observed 
among any of the experimental groups in terms of laten-
cy to find the platform, swimming distance or swimming 
speed during training (online suppl. fig.  1a–c; for all 
 online suppl. material, see www.karger.com/doi/10.1159/
000336074), nor in the probe trial performed 4 h after the 
last training section ( fig. 1 b). Thus all animals were able 
to learn the location of the platform, and showed compa-
rable short-term memory retention. However, LPS-treat-
ed mice displayed impaired long-term memory retention, 
as indicated by a significantly reduced time spent in the 
correct quadrant compared to control mice when tested 
in the probe trial 24 h after training ( fig. 1 c). These find-
ings suggest that curcumin pretreatment ameliorates a 
memory consolidation deficit induced by LPS. Although 
the comparable performances during the learning and 
the first probe trials argued against any interference due 
to LPS-induced motor function impairment, we further 
evaluated the motor skills of the mice using a rotarod 
 apparatus. LPS-treated mice displayed motor problems 
during the first 2 days after treatment, with a reduced 
time spent on the rotating rod ( fig. 1 d) and an increased 
number of falls ( fig. 1 e). Their performance became in-
distinguishable from the other groups by 72 h after LPS 
administration ( fig. 1 d). Notably, curcumin pretreatment 
prevented the LPS-induced deficits in rotarod perfor-
mance ( fig. 1 d, e), as well as the anxiety-like behaviors 
exhibited by the LPS-treated mice in the open field test 
( fig. 1 f, g). Similarly to what was observed in the Morris 
water maze, all animals equally learned to associate a 
tone with an electric shock in the fear conditioning para-
digm (online suppl. fig.  1d), and performed identically 
during the amygdala-dependent cued test (online suppl. 
table 1). However, in the hippocampus-dependent con-
textual fear paradigm the LPS-treated mice froze less 
than the control group, an effect again ameliorated by 
curcumin pretreatment ( fig. 1 h). Collectively, our results 
suggest that LPS causes cognitive impairment, specifi-
cally a deficit in long-term memory retention, which can 
be ameliorated by a short-term curcumin pretreatment.
 Curcumin Reduces Peripheral and CNS Inflammation 
 Long-term curcumin administration has been shown 
to exert anti-inflammatory  [29] and neuroprotective ef-
fects in several experimental models  [30] . Because we opt-
ed for a short-term pretreatment, we examined the extent 
of inflammation by measuring pro-inflammatory mark-
ers in the serum and hippocampus at early (4 h) and late 
(7 days) time points after drug administration. LPS caused 
a significant increase of TNF-  and IL-1  levels which 
was prevented by curcumin pretreatment administered 
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either systemically ( fig. 2 a, b) or in the brain ( fig. 2 c, d). In 
the hippocampus, the protein levels of nitric oxide syn-
thase (NOS), glial fibrillary acidic protein (GFAP), and the 
nuclear translocation of RelA (NF-  B activation) were el-
evated in response to LPS, and curcumin prevented the 
latter inflammatory cell responses ( fig. 2 f). One week af-
ter LPS exposure, the levels of TNF-  , IL-1  and NOS 
returned to basal levels (online suppl. table 2), while mark-
ers of NF-  B and glial cell activation remained signifi-
cantly elevated only in the LPS-treated group ( fig. 2 e).
 Curcumin Requires TNF-  Signaling to Prevent the 
Adverse Effects of LPS on Cognitive Function 
 Cytokines can influence cognition, and TNF-  is con-
sidered a key cytokine in the pro-inflammatory process 
 [31] . To investigate the role played by TNF-  signaling in 
the LPS-induced cognitive impairment and curcumin 
protection, we performed behavioral testing using a 
TNFR1 and TNFR2 DKO mouse model which is com-
pletely devoid of TNF-  signaling  [32] . The effects of LPS 
on rotarod performance in DKO mice were comparable 
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to those observed in WT mice with decreased latency 
time to fall ( fig. 3 a) and increased number of falls (data 
not shown) during the first 2 days after treatment, and 
full recovery by the third day. However, in DKO mice, 
curcumin failed to prevent LPS-induced sickness ( fig. 3 a). 
As recently reported  [33] , in the open field, DKO mice 
were overall less anxious than WT mice, spending more 
time in the center of the field (WT, C = 6.26  8 0.61%; 
DKO, C = 15.8  8 1.56%). LPS treatment diminished the 
distance traveled regardless of the type of pretreatment 
( fig. 3 b). During the nonspatial visible platform variant of 
the water maze, DKO mice spent most of the time float-
ing in the pool, and swam toward the visible platform 
only when prompted. This lack of motivation agrees with 
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 Fig. 4. Curcumin modulates glutamate and BDNF signaling. Lev-
els of glutaminase transcript were measured by quantitative RT-
PCR in WT ( a ) and DKO ( b ) mice treated according to the ex-
perimental protocol and euthanized 4 h after LPS (n = 4–5). Re-
sults of immunoblot analysis of glutamate transporters (EAAT2 
and EAAT3) and glutamate receptor subunits (GluR1 and NR1) 
in the hippocampus of WT mice ( c ) and DKO mice ( d ) (n = 3–10). 
Levels of mRNAs encoding BDNF and its receptor TrkB were 
measured by quantitative RT-PCR in samples from the hippo-
campus of WT mice ( e ,  g ) and DKO mice ( f , h ) (n = 3–6).  *  p  ! 
0.05 versus control;  * *  p  ! 0.01 versus control;  #  p  ! 0.05 versus 
LPS;  ###  p  ! 0.001 versus LPS.  i Relative levels of BDNF mRNA 
splice variants IV in hippocampal samples from WT and DKO 
mice.  * * *  p  ! 0.001 compared to the same treatment in WT mice. 
 Fig. 5. Curcumin upregulates TNFR2 and prevents glutamate-
induced excitotoxicity.  a Relative expression of TNFR2 in hippo-
campi from WT mice treated with LPS.  b Primary neuronal cul-
tures were incubated with vehicle or 10   M curcumin (Curc) for 
24 h, then challenged with 200   M glutamate (Glu). Levels of 
 TNFRs were measured 1 h after glutamate addition. Cell viability 
assessed by MTS assay ( c , hippocampal and  d , cortical), and lac-
tate dehydrogenase (LDH) release assay ( e , hippocampal and  f , 
cortical). Survival of hippocampal neurons incubated with re-
combinant TNFR2 (rT2) ( g ) or anti-TNFR2 and IgG control ( h ) 
before glutamate challenge. All data are mean and SEM of 3–5 
separate experiments.  *  p  ! 0.05 versus control;  * * *  p  ! 0.001 ver-
sus control;  ##  p  ! 0.01 versus glutamate. 
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the open field observation of an anxiolytic effect of TNFR 
deficiency, yet prevented us from testing hippocampus-
dependent memory in the water maze. During the learn-
ing and cued portions of the fear conditioning test, no 
differences were observed between groups (online suppl. 
table 1), while in the contextual phase LPS caused a sig-
nificant decrease in freezing which was not modified by 
curcumin pretreatment ( fig. 3 c).
 TNF-  Signaling Is Required for CNS LPS-Induced 
Inflammatory Responses but Is Dispensable for 
Peripheral Inflammatory Responses 
 The results of behavioral testing indicated that LPS-
induced cognitive impairment does not require TNF-  
signaling, while curcumin’s counteractive actions do. To 
better understand the latter findings in the context of cel-
lular inflammatory signaling, we evaluated peripheral 
LPS
Curcumin
TNFR2
GLS1
NR1
Survival
Plasticity
TrkB
BDNF
EAAT2
Gluglutamate
Cell survival
Cognitive
preservation
GLS1
Glu glutamate
GlutamateTNFR2
mTNF-
b
LPS
GLS1
GLS1
Glu
NR1
Ca2+
Glu
glutamate
glutamate
Glutamate
Cell dysfunction
Cell death
Cognitive impairment
TNFR1
sTNF-
a
 Fig. 6. Schematic of the protective mecha-
nisms of curcumin against innate im-
mune-induced neuronal dysfunction.
 a LPS causes increased glutamate produc-
tion and release (red dots) which may re-
sult in overstimulation of NMDA recep-
tors, increased intracellular Ca 2+ and neu-
ronal dysfunction.  b In the presence of 
curcumin, LPS induces an upregulation of 
TNFR2 (pink). TNFR2 may exert signal-
ing via binding to transmembrane TNF-  
(mTNF-  ), and it can be shed resulting in 
decrease sTNF-  /TNFR1 (yellow) signal-
ing. Changes in TNFR1/TNFR2 signaling 
are associated with a decrease of glutama-
tergic response through inhibition of glu-
taminase (GLS1) and NMDA receptor ac-
tivity coupled with increased EAAT2
glutamate reuptake. Together with the
enhancement of BDNF/TrkB (blue dots) 
signaling, these reactions appear to result 
in the preservation of neuronal functional 
integrity and cognitive performance. For 
colors, see online version. 
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and CNS inflammatory responses to LPS in DKO mice. 
As previously reported  [34] , we found that compared to 
WT mice, DKO mice have higher basal serum levels of 
TNF-  (WT = 0.28  8 0.07; DKO = 4.34  8 3.55 pg/  g 
proteins). The serum levels of TNF-  and IL-1  were 
both increased by LPS administration with curcumin 
only preventing IL-1  upregulation ( fig. 3 d, e). These data 
demonstrate that in DKO mice the peripheral inflamma-
tory response to LPS is not impaired, that curcumin anti-
inflammatory properties are overall unchanged, and that 
the decreased TNF-  levels found in the curcumin + LPS 
group among WT mice are likely not the result of reduced 
TNF-  production. In DKO mice, hippocampal levels of 
TNF-  and IL-1  ( fig. 3 f, g), as well as GFAP, NOS and 
nuclear RelA ( fig. 3 h) were not significantly affected by 
LPS or curcumin, indicating that contrary to the system-
ic response, CNS glia activation and cytokine production 
in response to LPS depends upon TNF-  signaling. Tak-
en together with the behavioral data, our findings suggest 
that: (1) pro-inflammatory cytokines may not be respon-
sible for the LPS-induced cognitive impairment; (2) the 
ability of curcumin to prevent the action of LPS on be-
havior does not depend upon its anti-inflammatory prop-
erties, and (3) curcumin’s mechanism of action requires 
intact TNFR signaling.
 Curcumin Modifies Glutamate Signaling 
 Glutamate signaling is essential for hippocampus-de-
pendent spatial working memory  [35] . However, high ex-
tracellular levels of glutamate and overactivation of glu-
tamate receptors may result in sustained elevation of in-
tracellular calcium levels, neuronal dysfunction and cell 
death  [36] . Increased glutamate levels have been shown 
following LPS administration  [37] . We tested how LPS 
and/or curcumin impacted glutamate signaling by mea-
suring levels of glutaminase, glutamate transporters and 
glutamate receptors in hippocampal tissue samples from 
WT and DKO mice. Glutaminase (GLS1) is a mitochon-
drial enzyme essential for the production of glutamate 
present in neurons and glia  [38] . GLS1 deregulation and 
increased glutamate production have been demonstrated 
in vitro for TNF  - and LPS-activated microglia cells  [39–
41] . We found an LPS-induced upregulation of hippo-
campal GLS1 transcript levels in both mouse strains, 
which was prevented by curcumin only in WT mice 
( fig. 4 a, b).
 Excitatory amino acid transporters (EAATs) are re-
sponsible for the reuptake of glutamate from the synaptic 
cleft, thus playing a fundamental role in the termination 
of the glutamatergic signal and the preservation of the lo-
cal integrity of excitatory synaptic transmission. We fo-
cused our analysis on EAAT2 and EAAT3. EAAT2 is al-
most exclusively expressed in glia, and is responsible for 
90% of forebrain glutamate reuptake  [42] . EAAT3 is the 
predominant post- and presynaptic neuronal transporter 
accounting for about 40% of hippocampal glutamate 
transport  [43] . Levels of EAAT3 were unchanged, while 
levels of EAAT2 were significantly upregulated in WT 
mice that received curcumin or curcumin plus LPS 
( fig.  4 c). In contrast, EAAT2 levels were not affected
by curcumin in DKO mice ( fig. 4 d). EAAT2 levels were 
comparable in all groups and strains by day 7 (data not 
shown). The   -amino-3-hydroxy-5-methylisoxazole-4-
propionic acid (AMPA) subunit GluR1 and the N-meth-
yl- D -aspartate (NMDA) subunit NR1 play important 
roles in learning and memory processes  [44] . In our ex-
perimental model, neither LPS nor curcumin significant-
ly affected hippocampal levels of GluR1 ( fig.  4 c), NR1 
( fig. 4 c), or NR2B (control = 1.0  8 0.09; LPS = 1.0  8 0.13; 
curcumin = 0.89  8 0.08; curcumin + LPS = 0.98  8 0.09). 
However, in WT mice, the phosphorylation of NR1 on 
Ser897 was reduced by more than 50% in all mice that 
received curcumin ( fig. 4 c). Changes in phosphorylation 
were specific for NR1 as demonstrated by the lack of 
changes in GluR1 phosphorylation levels ( fig.  4 c), and 
were absent in DKO mice ( fig. 4 d). Similarly to EAAT2, 
levels of phosphorylated NR1 returned to basal values by 
day 7 (data not shown). The phosphorylation of Ser897 of 
NR1 is associated with increased receptor sensitivity to 
glutamate and Ca 2+ currents  [45] . In WT mice, curcumin 
pretreatment may thus result in decreased amplitude of 
NMDA-driven calcium influx and possibly reduced neu-
ronal dysfunction. In DKO mice, the combined increase 
of glutaminase levels, with normal EAAT2 levels, and 
NMDA and AMPA receptor activity suggests a scenario 
in which release of glutamate from the presynaptic termi-
nal during the learning process may be exaggerated and 
possibly deleterious.
 Curcumin Upregulates BDNF Signaling 
 BDNF plays an important role in learning and mem-
ory, anxiety behaviors and neuroprotection  [46] . In our 
model, we found that in WT mice, the relative levels of 
BDNF mRNA were upregulated in response to curcu-
min treatment ( fig. 4 e), while TrkB mRNA levels were 
significantly elevated only in the curcumin + LPS group 
( fig. 4 g). In DKO mice, total levels of BDNF mRNA were 
similar in all groups ( fig.  4 f), and there was a statisti-
cally significant reduction in TrkB mRNA levels in LPS-
treated mice ( fig. 4 h). The transcriptional regulation of 
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BDNF is quite complex and generates various transcripts 
from which an identical BDNF protein is produced. In 
the rodent brain, promoter IV accounts for the majority 
of the activity-dependent BDNF expression  [47] . Inter-
estingly, the most striking difference between WT and 
DKO mice concerned BDNF-IV, which exhibited oppo-
site changes in expression in response to curcumin in 
WT mice (upregulation) and DKO mice (downregula-
tion) ( fig. 4 i). Notably, BDNF-IV is also the only tran-
script that has been shown to be modulated by TNF-  
 [48] .
 Curcumin Modulates TNFR2 Levels, and TNFR2 
Activation Mediates an Excitoprotective Action of 
Curcumin 
 TNF-  plays complex roles in the CNS depending 
upon which type of receptor is engaged  [49] . Activation 
of TNFR1 signaling pathways is generally linked to apop-
tosis, and in microglia it promotes glutamate release fa-
cilitating excitotoxicity  [39] . On the other hand, TNF-  
signaling via TNFR2 has been shown to be neuropro-
tective and neurotrophic  [50–52] . Curcumin failure to 
protect against LPS-induced changes in DKO mice 
prompted us to measure levels of TNFR1 and TNFR2 in 
the hippocampus of WT mice. Notably, TNFR2 was sig-
nificantly upregulated early on in mice receiving cur-
cumin + LPS ( fig. 5 a), returning to normal levels 1 week 
after LPS administration. To understand how curcumin-
induced TNFR2 upregulation may impact neurons we 
moved to a cell culture system. Similarly to what was ob-
served in vivo , TNFR1 levels were unaffected while 
TNFR2 levels were upregulated within 1 h in cells treated 
with curcumin and glutamate ( fig. 5 b). Curcumin pre-
treatment resulted in a significant decrease of glutamate-
induced cell death in both hippocampal ( fig. 5 c, e) and 
cortical neurons ( fig. 5 d, f). To assess the role played by 
TNFR2 in curcumin-induced cell protection, we used 
two different approaches, soluble recombinant TNFR2 
(rT2; a fusion protein containing the TNFR2 extracellu-
lar domain fused to the Fc of IgG, which acts as a decoy 
receptor to decrease levels of soluble TNF-  ) and a 
 TNFR2-neutralizing antibody. The addition of rT2 to
the culture medium before glutamate exposure prevented 
neuronal cell death to an extent similar to curcumin 
( fig. 5 g). On the other hand, the use of an antibody against 
the extracellular domain of TNFR2 exacerbated gluta-
mate toxicity and completely nullified the protection af-
forded by curcumin ( fig. 5 h). These results are consistent 
with previous reports showing that TNFR2 signaling 
promotes neuronal survival  [49, 52] .
 Discussion 
 Cognitive decline is associated with many neurode-
generative disorders, and neuroinflammation is believed 
to play a prominent role in the underlying synaptic dys-
function and neuronal degeneration  [1] . However, in view 
of recent findings highlighting physiological roles for cy-
tokines in the establishment and maintenance of learning 
and memory, the use of broad-spectrum anti-inflamma-
tory therapies for chronic neurodegenerative disorders 
may be ineffective or even detrimental. An extensive ar-
ray of health benefits attributed to curcumin has been 
identified in studies involving long-term supplementa-
tion (i.e., 4 weeks or longer)  [53] . In contrast, there have 
been few studies to evaluate the prophylactic efficacy of 
short-term administration of curcumin. The data in the 
present study provide novel insight into the mechanism 
by which innate immune activation perturbs cognition, 
and how curcumin counteracts its adverse effects. Our 
findings suggest that: (1) cognitive impairment caused by 
activation of TLR4 is not mediated by TNF-  ; (2) short-
term administration of curcumin ameliorates cognitive 
deficits with a mechanism requiring TNFR signaling, 
and (3) curcumin-induced upregulation of TNFR2 is re-
quired to protect neurons from excitotoxicity.
 Using LPS to elicit an immune response, we observed 
impairment of hippocampus-dependent memory which 
was efficiently prevented by a short-term supplemen-
tation with curcumin. The observed deficits were not
the result of sickness behavior or learning differences 
amongst the experimental groups, but instead resulted 
from impaired memory consolidation. This result is in 
agreement with previous findings in rats, which the au-
thors attributed to IL-1  upregulation  [54] . However, our 
data strongly argue against an IL-1  -dependent neuroin-
flammatory mechanism. In fact, curcumin was able to 
normalize IL-1  levels in both WT and DKO mice, and 
hippocampus glial activation and cytokine levels were 
unchanged in DKO mice, in which LPS caused behav-
ioral impairment even in the presence of curcumin. 
These observations suggest that LPS-induced cognitive 
impairment is not mediated by TNF-  signaling, and ap-
pears to involve a signaling pathway that does not require 
glial cell activation nor NF-  B-mediated cytokine pro-
duction. TLRs are expressed in astrocytes, microglia and 
neurons wherein their activation can affect neuronal 
plasticity and survival  [22, 26] . Specifically, TLR4 activa-
tion regulates neural progenitor cell self-renewal and 
neuronal differentiation  [55] , increases neuronal vulner-
ability to ischemia  [22] , regulates pain through the ex-
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pression of nociceptin, and increases excitability of dorsal 
root ganglion neurons  [56] . Also, TLR4 activation in pa-
renchymal cells is alone sufficient to drive a typical 
 acute-phase response to pathogens  [57] .
 Our results highlight a new mechanism by which cur-
cumin protects neurons against stress. We found that in 
the presence of a stressor curcumin induced the expres-
sion of TNFR2 both in vivo and in cultured neurons. This 
upregulation is fundamental for neuroprotection by cur-
cumin because the ability of curcumin to ameliorate LPS-
induced cognitive impairment and perturbations in the 
expression of glutaminase, NR1, EAAT2 and BDNF was 
absent in mice lacking TNFRs. Moreover, blockage of 
TNFR2 impaired curcumin-mediated neuroprotection, 
while addition of recombinant TNFR2 (which decreases 
soluble TNF-  /TNFR1 signaling) was as efficient as cur-
cumin itself in protecting neurons against glutamate tox-
icity. We therefore propose that curcumin protects neu-
rons against innate immune activation-induced cogni-
tive impairment by triggering a shift from TNFR1- to 
TNFR2-mediated TNF-  signaling ( fig. 6 ). Our model is 
supported by the recent observation that neuronal levels 
of TNFR2 are decreased while TNFR1 levels and its sig-
naling are increased in the brains of AD patients com-
pared to nondemented subjects  [58] . TNFR1-mediated 
signaling has been shown to impair learning and memo-
ry in neurodegenerative mouse models  [59] . Moreover, 
lack of TNFR2 exacerbates cognitive dysfunction after 
traumatic brain injury, while TNFR1 ablation amelio-
rates the cognitive deficit  [60] . In addition, deletion of 
TNFR1 has been shown to decrease fear conditioning re-
sponse  [61] . Furthermore, while TNF-  does not seem to 
play a major role in acute plasticity, as shown by equiva-
lent long-term potentiation responses in DKO and WT 
mice  [62] , it is required for homeostatic synaptic scaling 
and stabilization of neuronal network function  [63] . 
TNF-  and BDNF have been shown to be important for 
maintaining synapses in a plastic state in which scaling 
can be expressed. TNFR1-dependent TNF-  signaling 
‘scales up’ excitatory synapses by increasing cell surface 
AMPA receptors and reducing inhibitory GABA A recep-
tors  [62, 64] . However, TNFR1-dependent signaling also 
modifies AMPA receptor stoichiometry making the 
channels Ca 2+ permeable and so rendering neurons more 
susceptible to excitotoxicity  [62] . On the other hand, 
BDNF has been shown to inhibit neuronal excitability 
 [63] , and affords neuroprotection in animal models of a 
range of neurodegenerative disorders  [46] . We found 
that, in the presence of LPS, curcumin modulates factors 
underlying synaptic scaling (TNF-  and BDNF) result-
ing in amelioration of cognitive deficits and enhanced 
neuronal resistance to excitotoxic damage.
 Curcumin increased TNFR2 levels in the hippocam-
pus of WT mice and protected against LPS-induced mem-
ory impairment, and these effects of curcumin were lost 
in DKO mice suggesting a fundamental role for a switch 
from TNFR1 to TNFR2 signaling to control neuronal net-
work functionality in the mechanism of action of cur-
cumin. TNF-  signaling is being pursued as a poten-
tial therapeutic target for neurodegenerative disorders. 
Among the different strategies developed to mod ulate 
TNF-  signaling are monomeric and dimeric  (etanercept) 
TNFR2-Fc. Originally developed as TNF-  scavengers,
it has become evident that their mechanism of action
includes blockage of soluble TNF-  and induction of 
transmembrane TNF-  -TNFR2-mediated signaling  [65] . 
Etanercept has been shown to increase transmembrane 
TNF-   [66] , and to trigger transmembrane TNF-  re-
verse signaling that may induce cytokine suppression 
and/or other cellular events. While perispinal administra-
tion of etanercept improved cognitive per formance in AD 
patients in two small nonrandomized studies  [67] , large 
controlled trials to test its efficacy have not yet been com-
pleted (www.clinicaltrials.org NCT01068353). Indirect 
evidence substantiating the validity of TNFR2-Fc in AD 
comes from a recent study demonstrating a 55% decreased 
incidence of AD in rheumatoid arthritis patients treated 
with etanercept versus those who received other drugs 
such as prednisone, sulfasalazine and rituximab  [68] . 
While effective in several models of autoimmune disor-
ders, a substantial drawback of the use of TNFR2-Fc is the 
high cost associated with the therapy.
 Curcumin has been shown to ameliorate cognitive im-
pairment in several animal models, and consumption of 
curry has been associated with lower risk of AD  [69] and 
improved cognitive performance in elderly subjects  [21] . 
However, large trials to determine the impact of curcu-
min on cognitive performance in neurodegenerative dis-
orders have not yet been performed. The results of our 
study support the possible beneficial action of curcumin 
in treating cognitive impairment.
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